Leaflet DAKLINZA 30mg film-coated tablets
Indicated for: chronic hepatitis C
Route of administration: oral
Substance: daclatasvir (antiviral)
ATC: J05AX14 (Antiinfectives for systemic use | Direct acting antivirals | Other antivirals)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Daclatasvir is an antiviral medication used for the treatment of chronic hepatitis C. It works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus, thereby helping to eliminate the infection.
The medication is taken orally, usually in combination with other antivirals such as sofosbuvir, to enhance treatment effectiveness. It is indicated for various genotypes of the hepatitis C virus.
Side effects may include fatigue, headache, nausea, and insomnia. In rare cases, allergic reactions or other severe side effects may occur. It is important to follow all medical recommendations during treatment.
Consult your doctor to discuss the benefits and risks of treatment with Daclatasvir. Regular monitoring is essential to ensure the success of the therapy.
General data about DAKLINZA 30mg
- Substance: daclatasvir
- Date of latest medicines list: 01-01-2019
- Product code: W61010001
- Concentration: 30mg
- Pharmaceutical form: film-coated tablets
- Quantity: 28
- Product type: Original
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for daclatasvir
- 30mg
- 60mg